NIDA supports development of combined anti-heroin and HIV vaccine

Related posts:

1. NIDA Avant-Garde-Medications Development Award winners announced Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA’s second Avant-Garde Awards for Innovative Medication Development Research. The two scientists, Dr. Thomas Kosten, of Baylor College of Medicine, Houston, and Dr. Peter Burkhard, of the University of Connecticut, Storrs, will each receive $500,000 per year for five years to […]...
2. First NIDA Avant-Garde Awards for Medications Development Research A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction. The recipients of the first-ever Avant-Garde Awards for Innovative Medication Development Research by the National Institute on Drug Abuse (NIDA), part of the National Institutes […]...
3. Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
4. Launches collaborative program with industry and researchers to spur therapeutic development The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens […]...
5. Blueprint empowers drug development for nervous system disorders The National Institutes of Health has made awards to investigators across the United States for an ambitious set of projects seeking to develop new drugs for disorders of the nervous system....
6. Mexican flu pandemic study supports social distancing Eighteen-day periods of mandatory school closures and other social distancing measures were associated with a 29 to 37 percent reduction in influenza transmission rates in Mexico during the 2009 pandemic. The research was carried out by scientists at the Fogarty International Center at the National Institutes of Health and published in PLoS Medicine....
7. Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
8. NIH Scientists Advance Universal Flu Vaccine A universal influenza vaccine — so-called because it could potentially provide protection from all flu strains for decades — may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
9. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
10. Recovery Act Funding, the NIEHS Supports Grantees Across the Country Recovery Act funding, the NIEHS supports grantees across the country working on issues related to nanotechnology...
11. Medicare, Aiming for Near-Normal, Blood Sugar Did Not Delay Combined Risk of Diabetic Damage for People With Long-standing Diabetes, NIH-Sponsored Trial Finds In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was […]...
12. NHGRI funds development of revolutionary DNA sequencing technologies Researchers today received more than $14 million in grants to develop DNA sequencing technologies that will rapidly sequence a person’s genome for $1000 or less. The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, awarded the grants to enable the everyday use of DNA sequencing technologies by biomedical researchers and […]...
13. Medicare Card, Scientists Identify Markers, Human Breast Cancer Cells, Linked to Development of an Aggressive, But Less Common Form of Breast Cancer Scientists have identified a group of surface markers on cells linked to an aggressive type of breast cancer called estrogen receptor-negative cancer. In this preliminary study, estrogen-negative breast cancer developed when three markers, CD44+, CD49fhi, and CD133hi were present simultaneously on the surface of human cells taken from breast cancer patients and transplanted into a […]...
14. Medicare Medical Care, Rapid Development of Drug-Resistant, 2009 H1N1 Influenza Reported in Two Cases Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function....
15. HIV Vaccine Awareness Day May 18, 2011 Thirty years since the first report of the disease we now know as AIDS, scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, continue advancing toward our goal of a vaccine to prevent HIV infection. I am optimistic that we will succeed....